Clinical trials: Liver Diseases, Alcoholic
Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis
Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST)
GLP-1 analogues represent new treatments in diabetes that cause weight loss. Their effect on NASH in humans is unknown. A decrease in Alanine Aminotransferase (ALT) has been reported in pooled Exenatide/Placebo and…
- Trial name
- REALIST (NCT03648554)
- Testing
- dulaglutide (TRULICITY®) 1.5 mg, reinforced dietary monitoring
- Where
- 9 sites in France
- Volunteers
- 93 people
- Sponsor
- Central Hospital, Nancy, France
Non-Alcoholic Fatty Liver Disease, Body Composition
Predicting Obesity Consequences Using Body Measure and Urine Metabolomics
This is a prospective observational study which will recruit up to 1200 participants over a two-year period to investigate whether non-invasive methods such as bioelectrical impedance analysis parameters and urine metabolic…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Body Composition, Electric Impedance
- Trial name
- NCT04989062
- Testing
- Fibroscan, Bioelectrical impedance analysis, Urine unclear magnetic resonance metabolomics
- Where
- Taiwan
- Volunteers
- 1,200 people
- Sponsor
- Chang Gung Memorial Hospital
Non-Alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic
Effects of Mindfulness Based Stress Reduction Intervention in Patients With Non-alcoholic Fatty Liver Disease
The purpose of this research study is to find out about the usefulness of mindfulness for weight loss and improvement of physical and mental health in people who have non-alcoholic fatty liver disease (NAFLD).
- Conditions
- Non-Alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, Obesity
- Trial name
- NCT05130346
- Testing
- Mindfulness Based Stress Reduction (MBSR)
- Where
- United States
- Sponsor
- Virginia Commonwealth University
Schizophrenia, Treatment-resistant Schizophrenia
Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
SchizOMICS is a Phase IV, multicenter, dose-flexible, open-label, randomized controlled clinical trial to evaluate the efficacy and safety of aripiprazole versus paliperidone using multi-omics data in patients with a first…
- Conditions
- Schizophrenia, Treatment-resistant Schizophrenia, Side Effect, Lipid Metabolism Disorders
- Trial name
- SchizOMICS (NCT06060886)
- Testing
- Aripiprazole, Paliperidone
- Volunteers
- 244 people
- Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
Chronic Liver Disease, Liver Fibrosis
Comparative Efficacy of Liver Fibrosis and Steatosis Assessment With Fibroscan and iLivTouch
This study is aimed to compare the results and operating characteristics of liver stiffness measurement with the use of Fibroscan (EchoSens, France) and iLivTouch (Wuxi Hisky Medical Technologies Co., China) in patients with…
- Conditions
- Chronic Liver Disease, Liver Fibrosis, Liver Steatoses
- Trial name
- OGIG-01-22-LF (NCT05224037)
- Testing
- iLivTouch
- Where
- Russia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Federal State Budgetary Scientific Institution
Type 2 Diabetes, Non-alcoholic Fatty Liver Disease
Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI
Participants will be persons with type 2 diabetes who are likely to have fatty liver disease. The investigators think that this medication will reduce fatty liver.
- Trial name
- NCT02263677
- Testing
- Sitagliptin
- Where
- United States
- Sponsor
- University of Missouri-Columbia
Liver Fibrosis Due to NASH
Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH
The primary objective of this study is to evaluate the safety and efficacy of SIM (formerly referred to as GS-6624) in adults with compensated cirrhosis due to Non-Alcoholic Steatohepatitis (NASH).
- Trial name
- NASH (NCT01672879)
- Testing
- SIM
- Where
- 59 sites in United States, Canada and 6 more
- Volunteers
- 259 people
- Sponsor
- Gilead Sciences
Alcoholic Liver Disease
French National MICMAF Cohort
Excessive alcohol consumption is a major public health problem, particularly in France. It is the leading cause of cirrhosis and hepatocellular carcinoma.
- Trial name
- MICMAF (NCT05895890)
- Testing
- Sequential sampling (stool, saliva, serum) .
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Alcoholic Hepatitis
PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis
Only patients suffering from a severe form of alcoholic hepatitis (Maddrey's discriminant function greater than 32) require medical treatment.
- Trial name
- PROCORNAC (NCT06956482)
- Testing
- N-Acetylcysteine (NAC) Treatment, Prednisolone, Prednisolone 10mg
- Where
- France
- Volunteers
- 477 people
- Sponsor
- University Hospital, Lille
Nonalcoholic Steatohepatitis
A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)
This study will evaluate the effect of each dose of MK-3655 versus placebo on the percentage of individuals with NASH resolution without worsening of fibrosis after 52 weeks.
- Trial name
- NCT04583423
- Testing
- MK-3655
- Where
- 180 sites in United States, Argentina and 22 more
- Volunteers
- 183 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Alcoholic Fatty Liver Disease
Functional Roll for Non-alcoholic Fatty Liver Disease
Background: Low physical activity and poor eating habits (incl. high fat and carbohydrates but low fiber intake) are the main reason of obesity epidemic in western societies.
- Trial name
- NAFLDroll (NCT04520724)
- Testing
- plant fiber, maltodextrin bar
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Pomeranian Medical University Szczecin
Non-Alcoholic Fatty Liver Disease
Tocotrienol as a Treatment for Non-alcoholic Fatty Liver Disease
Vitamin E's potential in treating non-alcoholic fatty liver disease (NAFLD) is attributed to its antioxidant properties. While tocopherols have shown significant results in NAFLD management, the powerful properties of…
- Trial name
- NCT06596382
- Testing
- Tocotrienol rich-vitamin E
- Where
- Malaysia
- Volunteers
- 264 people
- Sponsor
- National University of Malaysia
Non-alcoholic Steatohepatitis, Hepatic Impairment
A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
The goal of this phase 1 study is to assess the pharmacokinetics, safety and tolerability following multiple oral doses of TVB-2640 in subjects with mild, moderate, or severe hepatic impairment compared to healthy subjects with…
- Conditions
- Non-alcoholic Steatohepatitis, Hepatic Impairment, Cirrhosis
- Trial name
- NCT05835180
- Testing
- TVB-2640 - 50 mg
- Where
- 3 sites in United States, Hungary
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Sagimet Biosciences Inc.
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
This study will test a study drug called ALN-PNP with and without another drug that is used for controlling blood sugar, appetite, and weight (for example, tirzepatide), to see if it can help treat MASLD, also known as fatty…
- Trial name
- NCT07527910
- Testing
- ALN-PNP, Tirzepatide
- Where
- 9 sites in United States
- Volunteers
- 204 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetes Mellitus Type 2
Medium-term Effects of a Polyphenol-rich Beverage Based on Red Grape Pomace Extract on Non-alcoholic Fatty Liver Disease, Cardiometabolic Risk Profile and Gut Microbiota in Subjects with Type 2 Diabetes
Nonalcoholic fatty liver disease (NAFLD) is a liver disease characterized by an abnormal accumulation of fat not due to alcohol or drug consumption that can evolve into steatohepatitis (NASH), fibrosis and cirrhosis.
- Trial name
- PoLiFat (NCT06895018)
- Testing
- Supplementation with Polyphenol Rich Drink
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Federico II University
Familial Mediterranean Fever, Non-Alcoholic Fatty Liver Disease
Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Aerobic Exercise
Familial Mediterranean fever (FMF) affect liver and causes some dysfunctions including non-alcoholic fatty liver.. still exercise and diet limitation is the treatment for this case
- Trial name
- NCT07130318
- Testing
- exercise plus diet restriction, diet restriction
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
Nonalcoholic Fatty Liver
Crassostrea Gigas for Liver Health
This study aimed to observe whether a hydrolyzed oyster extract improves liver health in participants whose alanine transaminase (ALT) levels are1-3 fold above the normal.
- Trial name
- NCT02992470
- Testing
- Hydrolyzed oyster extract
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Korean Medicine Hospital of Pusan National University
Carcinoma, Hepatocellular, Hepatitis, Viral, Human
Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis
The recurrence of hepatocellular carcinoma (HCC), two years after curative treatment is high, about 40% - 50%. Recently, it has been shown that intra-arterial radioactive lipiodol (Lipiocis®) could reduce the recurrence of cancer…
- Trial name
- Lipiocis (NCT00116454)
- Testing
- 131 I-lipiodol
- Where
- France
- Volunteers
- 73 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Alcoholic Hepatitis, Alcoholic Cirrhosis
Validation of the Procedure of Early Liver Transplantation in Alcoholic Hepatitis Resisting to Medical Treatment
The purpose of this study is to validate a strategy of identification of patients for early liver transplantation in severe alcoholic hepatitis. In this setting, short-term survival is very low (approx.
- Trial name
- QuickTrans (NCT01756794)
- Testing
- Liver transplantation
- Where
- 32 sites in Belgium, France
- Volunteers
- 284 people
- Sponsor
- University Hospital, Lille
Obesity, Metabolic Disease
The Danish Childhood Obesity Biobank
The Danish Childhood Obesity Biobank aims to produce a scientific platform for research in obesity: Bio-clinical data are collected from two cohorts - an obesity clinic cohort and a population-based cohort.
- Conditions
- Obesity, Metabolic Disease, NAFLD, Non-alcoholic Fatty Liver Disease, Cardiovascular Diseases
- Trial name
- NCT00928473
- Testing
- A family-centered, multidisciplinary obesity treatment program
- Where
- Denmark
- Volunteers
- 5,000 people
- Sponsor
- Zealand University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.